Tboone302

Decipher Urologic Cancer Sr. Genomic Rep. NJ/DE
I wish I was Ian Rankin, he is living my best life

[Rudy Willingham @RudyWillingham]

130 paper cutouts of OG Anunoby’s tip-in for the New York Knicks (aka the greatest play in NBA Finals history )

[Veracyte, Inc. @Veracyte]

New @CBSLosAngeles coverage of the landmark #OPTIMA trial shows how the Prosigna® Breast Risk of Recurrence (ROR) test can help clinicians and patients understand whether chemotherapy may be beneficial or safely avoided.

🎬 Watch the segment: https://t.co/4d5MDYJUDe

| About the #ProsignaTest |

🔗 Clinical resources - https://t.co/vGSwkG60Z9

🔗 How to order - https://t.co/xTz4mIEmbD

#ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGFugi

[Decipher by Veracyte @Decipher_VCYT]

Join us in New York, NY, June 19–20 for the NYU Advances in Screening, Detection, and Treatment of Prostate Cancer meeting. Visit the #Decipher @Veracyte booth to learn how #DecipherProstate helps patients and providers make more informed #ProstateCancer treatment decisions.

[UroToday.com @urotoday]

Correlation between genomic classifier scores and upfront treatment selection in localized #ProstateCancer: A real-world U.S. population-based cohort study. @mleapman @YaleCancer sits down with @zklaassen_md @GACancerCenter presenting a population-level analysis linking SEER registry with Decipher® genomic classifier data in low and intermediate-risk prostate cancer patients. #WatchNow > https://t.co/z8y9fSnhyn @Decipher_VCYT

[Veracyte, Inc. @Veracyte]

We are thrilled to announce that the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer, is officially available to order in the U.S.!

Thank you to @Nasdaq for featuring us on their Times Square tower in honor of this important milestone in breast cancer care.

| Impact |

In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation can have a lasting impact on a patient's life.

On the heels of the landmark #OPTIMA trial readout at #ASCO26, the #ProsignaTest now offers clinicians and the patients not only a deeper understanding of individual risk of recurrence (ROR) for their hormone receptor positive (HR+) breast cancer, but for many, if chemotherapy can benefit them or if they may safely avoid it.

Developed from the #PAM50 genomic classifier, the Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence.

Additionally, the Prosigna Breast ROR test is the only test proven to be predictive for chemotherapy benefit for premenopausal and post-menopausal patients with high-clinical risk HR+ breast cancer with up to 9 positive lymph nodes.

| Access and Availability |

The Prosigna test is available to order through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by many commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients.

🔗 How to order the Prosigna test - https://t.co/xTz4mIEmbD

| Resources |

🔹 Prosigna test clinical resources - https://t.co/vGSwkG60Z9

🔹 View Prosigna test sample reports - https://t.co/diCrADlCyl

#ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

Congratulations to @UCL and the #OPTIMA investigator team on this incredible research featured on BBC Breakfast. 👏

Stories like Aileen Pritchard’s highlight the power of #PrecisionOncology in helping identify patients who can safely avoid unnecessary chemotherapy while still receiving the care that’s right for them.

We’re proud that Veracyte was part of this important work.

The Prosigna® Breast Risk of Recurrence (ROR) Test is now also available for ordering in the U.S., helping support more personalized treatment decisions for patients with early-stage #BreastCancer.

| About Prosigna Test |

#ProsignaRORTest Clinical Resources - https://t.co/vGSwkG60Z9

How to order the #ProsignaBreastTest - https://t.co/xTz4mIEmbD

#Oncology #Prosigna #BreastCancerResearch

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit: https://t.co/fQcKkGFugi

[Julian Chavarriaga @chavarriagaj]

#GU26 Dr Moningi examined Decipher in de novo mPCa:
🧬 Largest real-world linkage of transcriptomic + clinical data (n=135K)
🔎 509 de novo metastatic vs 10,689 matched localized
🔺 Higher Decipher scores (0.94 vs 0.75)
🔺 ↑ Luminal B (65%) & PTEN inactivity (25%)
🔺 More NCCN high/very high risk
Biology matches the phenotype — genomically aggressive from the start.

@ASCO @UroToday

[UroToday.com @urotoday]

Correlation between genomic classifier scores and upfront treatment selection in localized #ProstateCancer: A real-world U.S. population-based cohort study. @mleapman @YaleCancer sits down with @zklaassen_md @GACancerCenter presenting a population-level analysis linking SEER registry with Decipher® genomic classifier data in low and intermediate-risk prostate cancer patients. #WatchNow > https://t.co/z8y9fSnhyn @Decipher_VCYT

[Nitin Yerram M.D. @NitinYerram]

@saumyg is one of the sharpest minds in urologic oncology. If anyone can make the case for moving beyond pathology in bladder cancer, it’s him. So many advances in this area, including Decipher Bladder @Veracyte. Worth the listen! @GUOncologyNow

[BackTable Urology @_backtableUro]

What is the practical role of biomarkers in prostate cancer care? This week, @theusinghal and @RuchikaTalwarMD to break down the landscape of biomarkers and how they are shaping prostate cancer decisions across the continuum @Veracyte #URO301

https://t.co/oyM0h5C0dx

[Decipher by Veracyte @Decipher_VCYT]

We’re at the 4th Annual PCI Cancer Conference, May 1-2, Incline Village, NV! Visit our booth to learn how #DecipherProstate by @Veracyte , Inc. helps bring clarity & confidence to treatment planning. #UrologicCancer #PrecisionMedicine

[BackTable Urology @_backtableUro]

How do genetic classifiers actually fit into everyday clinical practice?

Dr. Carissa Chu walks through the practical steps of integrating genomic classifiers into clinical workflows, highlighting how results may inform perioperative and future adjuvant decision-making.

Watch the full episode here: https://t.co/kkFc2P7RAG

This content is sponsored by Veracyte.

#URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

[Decipher by Veracyte @Decipher_VCYT]

Swing by! #DecipherProstate by @Veracyte , Inc. is at the #ACRO2026 in Orlando, FL. Visit booth 302 today or tomorrow to learn how we’re helping transform #ProstateCancer care! #UrologicCancer #PrecisionMedicine

[Elai Davicioni @Davicioni]

Another great study from the @MGHMedicine team @MiyamotoDavid @drjefstathiou https://t.co/grdaMZs2ym AR splicing and further risk stratification in the secondary radiotherapy setting

[Elai Davicioni @Davicioni]

https://t.co/PU12kUWmY6 another great paper from the @MUSICUrology team @wandering_gu @theusinghal @StatMatt9 @rtdess describing a novel clinical-genomic staging scheme

[Veracyte, Inc. @Veracyte]

The Pathologist features a Q&A with Phil Febbo, MD, Chief Scientific Officer and Chief Medical Officer at Veracyte, exploring what the #STAMPEDE trial reveals about utilizing gene expression testing to predict chemotherapy benefits and help improve prostate cancer outcomes.

This comprehensive conversation examines the research that's shaping the future of precision medicine in prostate cancer care.

📄 Read the full Q&A: https://t.co/hCXcnrVLcL

#DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #GenomicTesting #ClinicalResearch #Pathology #CancerDiagnostics #PersonalizedMedicine #Biotech

[Decipher by Veracyte @Decipher_VCYT]

New study: Post-prostatectomy patients with #DecipherProstate high risk scores showed significantly higher rates of biochemical recurrence and adverse pathology. Scores >0.85 were associated with the highest recurrence incidence. #ProstateCancer Read more: https://t.co/uSlQ2TmDE0

[George S. Langberg @GeorgeSLangberg]

A seminal moment for British Basketball. Hailing from the United Kingdom, Amari & Tosan grew up playing soccer & found a passion for basketball later on in their childhoods. From growing up in the UK to carving out standout college careers in the States, Amari & Tos have become true pioneers for British basketball. They didn’t follow a path, they built one. Their journeys, different in style but similar in grit have turned them into key reference points for young British players searching for a blueprint. They’re not just representing British basketball abroad; they’re actively expanding what it can be 🇬🇧

[Elai Davicioni @Davicioni]

@JoepJdeJong @SanRaffaeleMI @AndreaNecchi @neerajaiims @CMercinelli @vale_tateo @shilpaonc @SpiessPhilippe @UroDocAsh @TheLancetOncol @drjefstathiou @PGrivasMDPhD Great meeting- thanks to the excellent hosts and faculty

[BackTable Urology @_backtableUro]

As the need for BCG alternatives grows, new therapies are under the spotlight. Dr. Amy Luckenbaugh reviews the evidence behind gemcitabine/docetaxel, including clinical trial data, cost considerations, and its role as a potential alternative to BCG. She also discusses TAR-200, a novel drug delivery system that enables prolonged dwell time, highlighting its early efficacy data, potential for use in BCG-refractory vs. BCG-naive disease, and ongoing clinical trials.

Watch the full episode here: https://t.co/0FlFE4AJOg
This campaign is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025.

#URO253 #bladdercancer #BCG #intravesicaltherapy #oncology #highgrade